SCHEMBL234757

SCHEMBL234757

CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ NR5A2 O00482 1/20 1.00
▸ NR5A1 Q13285 1/20 1.00
▸ MAPT P10636 3/20 0.88
▸ FABP3 P05413 1/20 0.78
▸ RECQL P46063 1/20 0.77
▸ ALDH1A1 P00352 1/20 0.68
▸ ADRA1D P25100 1/20 0.66
▸ PTAFR P25105 1/20 0.66
▸ HTR1D P28221 1/20 0.66
▸ HTR2C P28335 1/20 0.66
▸ ADRA1B P35368 1/20 0.66
▸ DRD3 P35462 1/20 0.66
▸ TMEM97 Q5BJF2 1/20 0.66
▸ LPAR3 Q9UBY5 3/20 0.63
▸ LPAR1 Q92633 2/20 0.63
▸ ENPP2 Q13822 1/20 0.63
▸ MAPK1 P28482 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ GMNN O75496 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL235513 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Colfosceril Palmitate SCHEMBL184776 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL234621 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL233979 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL22693933 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL17165029 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL237094 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL2135188 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL233582 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL235645 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177503-A1 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-06-05 — — US claimed
EP-4482511-A2 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS The Regents of The University of Michigan (US) 2025-01-01 — — EP claimed
US-20240382626-A1 IRRADIATION AMENABLE LIPOSOMAL DYE AGGREGATES AND METHODS OF SYNTHESIS AND USE THEREOF UNIV TEXAS (US) 2024-11-21 — — US claimed
WO-2024053974-A1 COMPOSITION FOR PHOTOTHERMAL THERAPY AND PREPARATION METHOD THEREFOR 서울대학교산학협력단 2024-03-14 — — WO claimed
WO-2023164476-A2 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-08-31 — — WO claimed
US-20230001010-A1 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-01-05 — — US claimed
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF CODIAK BIOSCIENCES, INC. (US) 2022-11-10 — — US claimed
US-20220287944-A1 SILK PERSONAL CARE COMPOSITIONS EVOLVED BY NATURE INC (US) 2022-09-15 — — US claimed
US-20220218878-A1 CONTROLLED HEAT DELIVERY COMPOSITIONS BAMBU VAULT LLC (US) 2022-07-14 — — US claimed
EP-4017537-A1 SILK PERSONAL CARE COMPOSITIONS Evolved by Nature, Inc. (US) 2022-06-29 — — EP claimed
EP-3999110-A1 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS The Regents of The University of Michigan (US) 2022-05-25 — — EP claimed
WO-2021035087-A1 SILK PERSONAL CARE COMPOSITIONS EVOLVED BY NATURE, INC. (US) 2021-02-25 — — WO claimed
WO-2021016082-A1 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-01-28 — — WO claimed
WO-2020243047-A1 CONTROLLED HEAT DELIVERY COMPOSITIONS BAMBU VAULT LLC (US) 2020-12-03 — — WO claimed
WO-2020241925-A1 LIPID NANOPARTICLE COMPLEX CAPTURING APTIDE FUSED WITH CELL-PENETRATING MATERIAL AND USE THEREOF 한국과학기술원 2020-12-03 — — WO claimed
US-20200376138-A1 LIPID NANO PARTICLE COMPLEX COMPRISING APTIDE FUSED WITH CELL PENETRATING MATERIALS AND USE SAME KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-03 — — US claimed
US-20180236409-A1 PERMSELECTIVE MEMBRANE AND METHOD FOR PRODUCING THE SAME KURITA WATER INDUSTRIES LTD. (JP) 2018-08-23 — — US claimed
US-20150031996-A1 SEMICONDUCTING POLYMER NANOPARTICLES AS PHOTOACOUSTIC MOLECULAR IMAGING PROBES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-01-29 — — US claimed
EP-4743090-A1 LIPOSOME ENCAPSULATED APOMORPHINE Liposome Holdings Limited (NZ) 2026-05-20 — — EP disclosed
US-20050238584-A1 Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography NATIONAL SCIENCE FOUNDATION 2005-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF EXOSC5, EXOSC4, EXOSC10 SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback